HER2/neu revisited: quality and interpretive issuesSYED SALAHUDDIN AHMED; IQBAL, Jabed; AYE AYE THIKE et al.Journal of clinical pathology. 2011, Vol 64, Num 2, pp 120-124, issn 0021-9746, 5 p.Article

Combinaisons de thérapies anti-HER2: deux balles pour une même cible !GONCALVES, Anthony.Bulletin du cancer. 2012, Vol 99, Num 9, pp 813-814, issn 0007-4551, 2 p.Article

Identification of tumorsphere-and tumor-initiating cells in HER2/Neu-lnduced mammary tumorsLIU, Jeff C; TAO DENG; LEHAL, Rajwinder S et al.Cancer research (Baltimore). 2007, Vol 67, Num 18, pp 8671-8681, issn 0008-5472, 11 p.Article

Biological properties of a human compact anti-ErbB2 antibodyDE LORENZO, Claudia; COZZOLINO, Rosanna; CARPENTIERI, Andrea et al.Carcinogenesis (New York. Print). 2005, Vol 26, Num 11, pp 1890-1895, issn 0143-3334, 6 p.Article

Her-2/neu overexpression and amplification in uterine papillary serous carcinomaSLOMOVITZ, Brian M; BROADDUS, Russell R; BURKE, Thomas W et al.Journal of clinical oncology. 2004, Vol 22, Num 15, pp 3126-3132, issn 0732-183X, 7 p.Conference Paper

Surexpression de HER2: un dictat ? = Overexpression of HER2: a dictat?COTTU, P.Société Française de Sénologie et de Pathologie Mammaire. Journées. 2011, pp 168-173, isbn 978-2-8178-0248-0, 1Vol, 6 p.Conference Paper

Is HER2/neu expressed in nonepithelial ovarian malignancies?MENCZER, Joseph; SCHREIBER, Letizia; CZERNOBILSKY, Bernard et al.American journal of obstetrics and gynecology. 2007, Vol 196, Num 1, pp 79-80, issn 0002-9378, 2 p.Article

Targeting HER2 epitopesSUMANTA KUMAR PAL; PEGRAM, Mark.Seminars in oncology. 2006, Vol 33, Num 4, pp 386-391, issn 0093-7754, 6 p.Article

Downregulation of Muc1 in MMTV-c-Neu tumorsADRIANCE, Melissa C; GENDLER, Sandra J.Oncogene (Basingstoke). 2004, Vol 23, Num 3, pp 697-705, issn 0950-9232, 9 p.Article

Pertuzumab: Optimizing HER2 BlockadeMETZGER-FILHO, Otto; WINER, Eric P; KROP, Ian et al.Clinical cancer research (Print). 2013, Vol 19, Num 20, pp 5552-5556, issn 1078-0432, 5 p.Article

Age and Neu roi nfla m mation: A Lifetime of Psychoneuroimmune ConsequencesGODBOUT, Jonathan P; JOHNSON, RodneyW.Immunology and allergy clinics of North America. 2009, Vol 29, Num 2, issn 0889-8561, ix, 321-337 [18 p.]Article

GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formationTAO BAI; LUOH, Shiuh-Wen.Carcinogenesis (New York. Print). 2008, Vol 29, Num 3, pp 473-479, issn 0143-3334, 7 p.Article

Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary TumorsWORSCHECH, Andrea; KMIECIAK, Maciej; KNUTSON, Keith L et al.Cancer research (Baltimore). 2008, Vol 68, Num 7, pp 2436-2446, issn 0008-5472, 11 p.Article

Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner : Implications for progression of ErbB2-overexpressing tumorsLIXING ZHAN; BIN XIANG; MUTHUSWAMY, Senthil K et al.Cancer research (Baltimore). 2006, Vol 66, Num 10, pp 5201-5208, issn 0008-5472, 8 p.Article

Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulationGRABERT, Ryan C; COUSENS, Leslie P; SMITH, Janelle A et al.Clinical cancer research. 2006, Vol 12, Num 2, pp 569-576, issn 1078-0432, 8 p.Article

Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinomaBOFIN, Anna M; YTTERHUS, Borgny; MARTIN, Cara et al.American journal of clinical pathology. 2004, Vol 122, Num 1, pp 110-119, issn 0002-9173, 10 p.Article

Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccineDISIS, Mary L; SCHIFFMAN, Kathy; GUTHRIE, Katherine et al.Journal of clinical oncology. 2004, Vol 22, Num 10, pp 1916-1925, issn 0732-183X, 10 p.Article

Targeting of HER2 antigen for the treatment of disseminated peritoneal diseaseMILENIC, Diane E; GARMESTANI, Kayhan; BRADY, Erik D et al.Clinical cancer research. 2004, Vol 10, Num 23, pp 7834-7841, issn 1078-0432, 8 p.Article

Radionuclide therapy of HER2-positive microxenografts using a ¹⁷⁷Lu-labeled HER2-specific affibody moleculeTOLMACHEV, Vladimir; ORLOVA, Anna; WENNBORG, Anders et al.Cancer research (Baltimore). 2007, Vol 67, Num 6, pp 2773-2782, issn 0008-5472, 10 p.Article

Neu roblastoma: Biology, Prognosis, and TreatmentPARK, Julie R; EGGERT, Angelika; CARON, Huib et al.Hematology/oncology clinics of North America. 2010, Vol 24, Num 1, issn 0889-8588, viii, 65-86 [23 p.]Article

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02BENAVIDES, Linda C; GATES, Jeremy D; PEOPLES, George E et al.Clinical cancer research (Print). 2009, Vol 15, Num 8, pp 2895-2904, issn 1078-0432, 10 p.Article

HER2 testing in breast cancerCarlson, Robert W; Hammond, Elizabeth H; Allred, Craig et al.NCCN Task Force report. 2006, 1 cédéromBook

Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowthANDRECHEK, Eran R; WHITE, Donald; MULLER, William J et al.Oncogene (Basingstoke). 2005, Vol 24, Num 5, pp 932-937, issn 0950-9232, 6 p.Article

Virosomes as new carrier system for cancer vaccinesSCHWANINGER, Ruth; WAELTI, Ernst; ZAJAC, Paul et al.Cancer immunology and immunotherapy. 2004, Vol 53, Num 11, pp 1005-1017, issn 0340-7004, 13 p.Article

Her-2/Neu as a paradigm of a tumor-specific target for therapyCHOUDHURY, A; KIESSLING, R.Breast disease. 2004, Vol 20, pp 25-31, issn 0888-6008, 7 p.Article